Abbott Laboratories (ABT) 10-Q31 Jul 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover	6 Months Ended
Cover	Jun. 30, 2024 shares
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	1-2189
Entity Registrant Name	ABBOTT LABORATORIES
Entity Incorporation, State or Country Code	IL
Entity Tax Identification Number	36-0698440
Entity Address, Address Line One	100 Abbott Park Road
Entity Address, City or Town	Abbott Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	224
Local Phone Number	667-6100
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	1,739,897,004
Entity Central Index Key	0000001800
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false
NEW YORK STOCK EXCHANGE, INC.
Document and Entity Information
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	NYSE
CHICAGO STOCK EXCHANGE, INC
Document and Entity Information
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	CHX

Condensed Consolidated Statemen

Condensed Consolidated Statement of Earnings (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net sales	$ 10,377	$ 9,978	$ 20,341	$ 19,725
Cost of products sold, excluding amortization of intangible assets	4,603	4,483	9,066	8,814
Amortization of intangible assets	471	498	943	989
Research and development	698	715	1,382	1,369
Selling, general and administrative	2,936	2,740	5,895	5,502
Total operating cost and expenses	8,708	8,436	17,286	16,674
Operating earnings	1,669	1,542	3,055	3,051
Interest expense	140	159	281	312
Interest (income)	(82)	(98)	(162)	(199)
Net foreign exchange (gain) loss	(6)	21	(6)	27
Other (income) expense, net	10	(176)	(101)	(287)
Earnings before taxes	1,607	1,636	3,043	3,198
Taxes on earnings	305	261	516	505
Net Earnings	$ 1,302	$ 1,375	$ 2,527	$ 2,693
Basic Earnings Per Common Share (in dollars per share)	$ 0.74	$ 0.79	$ 1.45	$ 1.54
Diluted Earnings Per Common Share (in dollars per share)	$ 0.74	$ 0.78	$ 1.44	$ 1.53
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,743,040	1,740,359	1,741,595	1,741,051
Dilutive Common Stock Options (in shares)	8,113	9,889	8,781	9,933
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,751,153	1,750,248	1,750,376	1,750,984
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	8,855	5,474	6,892	5,474

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Statement of Comprehensive Income [Abstract]
Net Earnings	$ 1,302	$ 1,375	$ 2,527	$ 2,693
Foreign currency translation gain (loss) adjustments	(36)	(52)	(422)	87
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $— and $1 in 2024 and $(3) and $(3) in 2023	7	(6)	11	(4)
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $27 and $57 in 2024 and $4 and $(54) in 2023	60	26	115	(103)
Other comprehensive income (loss)	31	(32)	(296)	(20)
Comprehensive Income	1,333	$ 1,343	2,231	$ 2,673
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	(6,926)		(6,926)		$ (6,504)
Net actuarial (losses) and prior service (costs) and credits	(1,365)		(1,365)		(1,376)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges	156		156		41
Accumulated other comprehensive income (loss)	$ (8,135)		$ (8,135)		$ (7,839)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit)	$ 0	$ (3)	$ 1	$ (3)
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit)	$ 27	$ 4	$ 57	$ (54)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 6,987	$ 6,896
Short-term investments	232	383
Trade receivables, less allowances of $441 in 2024 and $444 in 2023	6,854	6,565
Inventories:
Finished products	4,060	3,946
Work in process	880	807
Materials	1,874	1,817
Total inventories	6,814	6,570
Prepaid expenses and other receivables	2,232	2,256
Total Current Assets	23,119	22,670
Investments	877	799
Property and equipment, at cost	22,061	21,933
Less: accumulated depreciation and amortization	11,828	11,779
Net property and equipment	10,233	10,154
Intangible assets, net of amortization	7,827	8,815
Goodwill	23,308	23,679
Deferred income taxes and other assets	7,653	7,097
Total Assets	73,017	73,214
Current Liabilities:
Trade accounts payable	4,125	4,295
Salaries, wages and commissions	1,389	1,597
Other accrued liabilities	5,071	5,422
Dividends payable	959	955
Income taxes payable	601	492
Current portion of long-term debt	1,615	1,080
Total Current Liabilities	13,760	13,841
Long-term debt	13,139	13,599
Post-employment obligations, deferred income taxes and other long-term liabilities	6,558	6,947
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	0	0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,990,029,292; 2023: 1,987,883,852	24,858	24,869
Common shares held in treasury, at cost — Shares: 2024: 250,131,563; 2023: 253,807,494	(15,759)	(15,981)
Earnings employed in the business	38,354	37,554
Accumulated other comprehensive income (loss)	(8,135)	(7,839)
Total Abbott Shareholders’ Investment	39,318	38,603
Noncontrolling Interests in Subsidiaries	242	224
Total Shareholders’ Investment	39,560	38,827
Total Liabilities and Shareholders' Investment	$ 73,017	$ 73,214

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Trade receivables, allowances	$ 441	$ 444
Preferred shares, par value (in dollars per share)	$ 1	$ 1
Preferred shares, authorized (in shares)	1,000,000	1,000,000
Preferred shares, issued (in shares)	0	0
Common shares, authorized (in shares)	2,400,000,000	2,400,000,000
Common shares, issued (in shares)	1,990,029,292	1,987,883,852
Common shares held in treasury (in shares)	250,131,563	253,807,494

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Shareholders' Investment (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Increase (Decrease) in Shareholders' Investment
Beginning balance			$ 38,827
Net earnings	$ 1,302	$ 1,375	2,527	$ 2,693
Other comprehensive income (loss)	31	(32)	(296)	(20)
Ending balance	39,560		39,560
Common Shares
Increase (Decrease) in Shareholders' Investment
Beginning balance	24,726	24,488	24,869	24,709
Issued under incentive stock programs	13	14	100	30
Share-based compensation	124	119	446	415
Issuance of restricted stock awards	(5)	(9)	(557)	(542)
Ending balance	24,858	24,612	24,858	24,612
Common Shares Held in Treasury
Increase (Decrease) in Shareholders' Investment
Beginning balance	(15,761)	(15,307)	(15,981)	(15,229)
Issued under incentive stock programs	2	10	244	252
Purchased	0	(425)	(22)	(745)
Ending balance	(15,759)	(15,722)	(15,759)	(15,722)
Earnings Employed in the Business
Increase (Decrease) in Shareholders' Investment
Beginning balance	38,011	35,868	37,554	35,257
Net earnings	1,302	1,375	2,527	2,693
Cash dividends declared on common shares	(961)	(889)	(1,921)	(1,779)
Effect of common and treasury share transactions	2	1	194	184
Ending balance	38,354	36,355	38,354	36,355
Accumulated Other Comprehensive Income (Loss)
Increase (Decrease) in Shareholders' Investment
Beginning balance	(8,166)	(8,039)	(7,839)	(8,051)
Other comprehensive income (loss)	31	(32)	(296)	(20)
Ending balance	(8,135)	(8,071)	(8,135)	(8,071)
Noncontrolling Interests in Subsidiaries
Increase (Decrease) in Shareholders' Investment
Beginning balance	233	222	224	219
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases	9	8	18	11
Ending balance	$ 242	$ 230	$ 242	$ 230

Condensed Consolidated Statem_5

Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Increase (Decrease) in Shareholders' Investment
Beginning balance, treasury stock, common (in shares)			253,807,494
Ending balance, treasury stock, common (in shares)	250,131,563		250,131,563
Common Shares
Increase (Decrease) in Shareholders' Investment
Beginning balance (in shares)	1,989,789,999	1,986,904,170	1,987,883,852	1,986,519,278
Issued under incentive stock programs (in shares)	239,293	277,321	2,145,440	662,213
Ending balance (in shares)	1,990,029,292	1,987,181,491	1,990,029,292	1,987,181,491
Common Shares Held in Treasury
Increase (Decrease) in Shareholders' Investment
Beginning balance, treasury stock, common (in shares)	250,155,515	247,957,371	253,807,494	248,724,257
Issued under incentive stock programs (in shares)	27,310	157,305	3,865,565	4,090,470
Purchased (in shares)	3,358	4,023,445	189,634	7,189,724
Ending balance, treasury stock, common (in shares)	250,131,563	251,823,511	250,131,563	251,823,511
Earnings Employed in the Business
Increase (Decrease) in Shareholders' Investment
Cash dividends declared on common shares (in dollars per share)	$ 0.55	$ 0.51	$ 1.10	$ 1.02

Condensed Consolidated Statem_6

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flow From (Used in) Operating Activities:
Net earnings	$ 2,527	$ 2,693
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation	667	617
Amortization of intangible assets	943	989
Share-based compensation	445	413
Trade receivables	(476)	37
Inventories	(513)	(667)
Other, net	(608)	(1,736)
Net Cash From Operating Activities	2,985	2,346
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(931)	(887)
Acquisitions of businesses and technologies, net of cash acquired	0	(826)
Proceeds from business dispositions	1	40
Sales (purchases) of other investment securities, net	49	(7)
Other	3	5
Net Cash From (Used in) Investing Activities	(878)	(1,675)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other	(170)	(29)
Proceeds from issuance of long-term debt	221	1
Repayments of long-term debt	(18)	(2)
Purchases of common shares	(229)	(966)
Proceeds from stock options exercised	147	77
Dividends paid	(1,918)	(1,780)
Net Cash From (Used in) Financing Activities	(1,967)	(2,699)
Effect of exchange rate changes on cash and cash equivalents	(49)	(19)
Net Increase (Decrease) in Cash and Cash Equivalents	91	(2,047)
Cash and Cash Equivalents, Beginning of Year	6,896	9,882
Cash and Cash Equivalents, End of Period	$ 6,987	$ 7,835

Basis of Presentation

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 — Basis of Presentation The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

New Accounting Standards

New Accounting Standards	6 Months Ended
New Accounting Standards	Jun. 30, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Standards	Note 2 — New Accounting Standards Recent Accounting Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.

Revenue

Revenue	6 Months Ended
Revenue	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Note 3 — Revenue Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The following tables provide detail by sales category: Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 (in millions) U.S. Int’l Total U.S. Int’l Total Established Pharmaceutical Products — Key Emerging Markets $ — $ 988 $ 988 $ — $ 990 $ 990 Other — 306 306 — 297 297 Total — 1,294 1,294 — 1,287 1,287 Nutritionals — Pediatric Nutritionals 564 495 1,059 507 517 1,024 Adult Nutritionals 369 722 1,091 374 678 1,052 Total 933 1,217 2,150 881 1,195 2,076 Diagnostics — Core Laboratory 327 1,002 1,329 311 982 1,293 Molecular 33 94 127 43 98 141 Point of Care 107 49 156 99 43 142 Rapid Diagnostics 345 238 583 508 233 741 Total 812 1,383 2,195 961 1,356 2,317 Medical Devices — Rhythm Management 292 315 607 269 314 583 Electrophysiology 287 340 627 245 308 553 Heart Failure 244 77 321 226 69 295 Vascular 275 449 724 264 451 715 Structural Heart 258 306 564 219 279 498 Neuromodulation 192 51 243 185 42 227 Diabetes Care 637 1,011 1,648 505 919 1,424 Total 2,185 2,549 4,734 1,913 2,382 4,295 Other 4 — 4 3 — 3 Total $ 3,934 $ 6,443 $ 10,377 $ 3,758 $ 6,220 $ 9,978 Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 (in millions) U.S. Int’l Total U.S. Int’l Total Established Pharmaceutical Products — Key Emerging Markets $ — $ 1,916 $ 1,916 $ — $ 1,902 $ 1,902 Other — 604 604 — 574 574 Total — 2,520 2,520 — 2,476 2,476 Nutritionals — Pediatric Nutritionals 1,078 990 2,068 966 982 1,948 Adult Nutritionals 733 1,417 2,150 727 1,368 2,095 Total 1,811 2,407 4,218 1,693 2,350 4,043 Diagnostics — Core Laboratory 637 1,897 2,534 600 1,875 2,475 Molecular 75 181 256 90 198 288 Point of Care 205 90 295 192 84 276 Rapid Diagnostics 826 498 1,324 1,414 552 1,966 Total 1,743 2,666 4,409 2,296 2,709 5,005 Medical Devices — Rhythm Management 563 606 1,169 529 581 1,110 Electrophysiology 556 658 1,214 483 575 1,058 Heart Failure 481 145 626 444 132 576 Vascular 529 884 1,413 482 850 1,332 Structural Heart 491 588 1,079 429 530 959 Neuromodulation 373 96 469 340 83 423 Diabetes Care 1,226 1,991 3,217 984 1,753 2,737 Total 4,219 4,968 9,187 3,691 4,504 8,195 Other 7 — 7 6 — 6 Total $ 7,780 $ 12,561 $ 20,341 $ 7,686 $ 12,039 $ 19,725 Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the second quarter of 2024 and 2023, COVID-19 testing-related sales totaled $102 million and $263 million, respectively. In the first six months of 2024 and 2023, Abbott’s COVID-19 testing-related sales totaled $306 million and $993 million, respectively. Remaining Performance Obligations As of June 30, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.8 billion in the Diagnostics segment and approximately $493 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter. These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Other Contract Assets and Liabilities Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements. Changes in the contract liabilities during the period are as follows: (in millions) Contract Liabilities: Balance at December 31, 2023 $ 545 Unearned revenue from cash received during the period 232 Revenue recognized related to contract liability balance (233) Balance at June 30, 2024 $ 544

Supplemental Financial Informat

Supplemental Financial Information	6 Months Ended
Supplemental Financial Information	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
Supplemental Financial Information	Note 4 — Supplemental Financial Information Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended June 30, 2024 and 2023 were $1.297 billion and $1.370 billion, respectively, and for the six months ended June 30, 2024 and 2023 were $2.517 billion and $2.682 billion, respectively. In the second quarter of 2024, Abbott sold a non-core business related to its Established Pharmaceutical Products segment. Abbott recorded a loss of approximately $143 million on the sale in Other (income) expense, net in its Condensed Consolidated Statement of Earnings. Net assets which primarily related to inventory and net property and equipment and had a carrying value of $28 million were included in the sale. The loss on the sale also included $116 million of cumulative foreign currency translation adjustment previously recorded in Accumulated other comprehensive income (loss). Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2024 includes $289 million of pension contributions and the payment of cash taxes of approximately $747 million. The first six months of 2023 included $290 million of pension contributions and the payment of cash taxes of approximately $837 million. The following summarizes the activity for the first six months of 2024 related to the allowance for doubtful accounts as of June 30, 2024: (in millions) Allowance for Doubtful Accounts: Balance at December 31, 2023 $ 241 Provisions/charges to income 42 Amounts charged off and other deductions (28) Balance at June 30, 2024 $ 255 The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances. The components of long-term investments as of June 30, 2024 and December 31, 2023 are as follows: (in millions) June 30, December 31, Long-term Investments: Equity securities $ 549 $ 555 Other 328 244 Total $ 877 $ 799 The increase in Abbott’s long-term investments as of June 30, 2024 versus the balance as of December 31, 2023 primarily relates to additional investments and earnings from equity method investments, partially offset by the impairment of certain securities. Abbott’s equity securities as of June 30, 2024 include $311 million of investments in mutual funds that are held in a rabbi trust. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency. Abbott also holds certain investments as of June 30, 2024 with a carrying value of $162 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $65 million that do not have a readily determinable fair value.

Changes In Accumulated Other Co

Changes In Accumulated Other Comprehensive Income (Loss)	6 Months Ended
Changes In Accumulated Other Comprehensive Income (Loss)	Jun. 30, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes In Accumulated Other Comprehensive Income (Loss)	Note 5 — Changes In Accumulated Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows: Three Months Ended June 30 Cumulative Foreign Net Actuarial (Losses) and Cumulative Gains (Losses) (in millions) 2024 2023 2024 2023 2024 2023 Balance at March 31 $ (6,890) $ (6,594) $ (1,372) $ (1,491) $ 96 $ 46 Other comprehensive income (loss) before reclassifications (152) (52) 3 1 77 80 Amounts reclassified from accumulated other comprehensive income 116 — 4 (7) (17) (54) Net current period comprehensive income (loss) (36) (52) 7 (6) 60 26 Balance at June 30 $ (6,926) $ (6,646) $ (1,365) $ (1,497) $ 156 $ 72 Six Months Ended June 30 Cumulative Foreign Net Actuarial (Losses) and Cumulative Gains (Losses) (in millions) 2024 2023 2024 2023 2024 2023 Balance at January 1 $ (6,504) $ (6,733) $ (1,376) $ (1,493) $ 41 $ 175 Other comprehensive income (loss) before reclassifications (538) 87 5 3 145 38 Amounts reclassified from accumulated other comprehensive income 116 — 6 (7) (30) (141) Net current period comprehensive income (loss) (422) 87 11 (4) 115 (103) Balance at June 30 $ (6,926) $ (6,646) $ (1,365) $ (1,497) $ 156 $ 72 Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 — Post-Employment Benefits for additional details.

Business Acquisition

Business Acquisition	6 Months Ended
Business Acquisition	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Business Acquisition	Note 6 — Business Acquisition On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which furthers Abbott's efforts to develop connected solutions for making diabetes management more personal and precise. The purchase price, the final allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements. On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million . The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
Goodwill and Intangible Assets	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 7 — Goodwill and Intangible Assets The total amount of goodwill reported was $23.3 billion at June 30, 2024 and $23.7 billion at December 31, 2023. The amount of goodwill related to reportable segments at June 30, 2024 was $2.6 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.9 billion for the Medical Devices segment. F oreign currency translation adjustments decreased goodwill by approximately $332 million in the first six months of 2024. Goodwill decreased $39 million due to the finalization of purchase accounting for business acquisitions. There were no reductions of goodwill relating to impairments in the first six months of 2024. The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.7 billion as of June 30, 2024 and December 31, 2023, respectively. Accumulated amortization was $20.5 billion and $19.7 billion as of June 30, 2024 and December 31, 2023, respectively. In the first six months of 2024, intangible assets decreased $46 million due to foreign currency translation and $8 million due to an impairment charge. Abbott’s estimated annual amortization expense for intangible assets is approximately $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026, $1.3 billion in 2027 and $0.7 billion in 2028. Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were approximately $798 million as of June 30, 2024 and $787 million as of December 31, 2023 . In the second quarter of 2024 ,

Restructuring Plans

Restructuring Plans	6 Months Ended
Restructuring Plans	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Plans	Note 8 — Restructuring Plans In 2024, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic, medical devices and nutritional businesses, including the discontinuation of its ZonePerfect ® product line. In the six months ended June 30, 2024, Abbott recorded employee related severance and other charges of $59 million, of which $38 million was recorded in Cost of products sold, $2 million was recorded in Research and development, and $19 million was recorded in Selling, general and administrative expenses. Payments related to these actions totaled $8 million in the first six months of 2024 and the remaining liabilities totaled $51 million at June 30, 2024. In addition, Abbott recognized asset impairment charges of $28 million related to these restructuring plans. In 2023 and 2022, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices, diagnostic, nutritional and established pharmaceutical businesses. The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2024: (in millions) Total Accrued balance at December 31, 2023 $ 137 Payments and other adjustments (69) Accrued balance at June 30, 2024 $ 68

Incentive Stock Programs

Incentive Stock Programs	6 Months Ended
Incentive Stock Programs	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Incentive Stock Programs	Note 9 — Incentive Stock Programs In the first six months of 2024, Abbott granted 1,683,097 stock options, 404,597 restricted stock awards and 5,265,995 restricted stock units under its incentive stock program. At June 30, 2024, approximately 60 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at June 30, 2024 is as follows: Outstanding Exercisable Number of shares 28,058,739 24,125,493 Weighted average remaining life (years) 4.8 4.2 Weighted average exercise price $ 78.94 $ 73.34 Aggregate intrinsic value (in millions) $ 815 $ 815 The total unrecognized share-based compensation cost at June 30, 2024 amounted to approximately $675 million which is expected to be recognized over the next three years.

Debt and Lines of Credit

Debt and Lines of Credit	6 Months Ended
Debt and Lines of Credit	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt and Lines of Credit	Note 10 — Debt and Lines of Credit On June 26, 2024, Abbott modified its existing, yen-denominated 5-year term loan scheduled to mature in November 2024. The amended terms include a net increase in principal debt from ¥59.8 billion to ¥92.0 billion, with a new maturity date in June 2029. The modified, 5-year term loan bears interest at the Tokyo Interbank Offered Rate (TIBOR) plus a fixed spread, and the interest rate is reset quarterly. The net proceeds equated to approximately $201 million. Abbott has readily available financial resources, including unused lines of credit that support commercial paper borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. On January 29, 2024, Abbott terminated its 2020 Five Year Credit Agreement (2020 Agreement) and entered into a new Five Year Credit Agreement (Revolving Credit Agreement). There were no outstanding borrowings under the 2020 Agreement at the time of its termination. Any borrowings under the Revolving Credit Agreement will mature and be payable on January 29, 2029 and will bear interest, at Abbott’s option, based on either a base rate or Secured Overnight Financing Rate (SOFR), plus an applicable margin based on Abbott’s credit ratings.

Financial Instruments, Derivati

Financial Instruments, Derivatives and Fair Value Measures	6 Months Ended
Financial Instruments, Derivatives and Fair Value Measures	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments, Derivatives and Fair Value Measures	Note 11 — Financial Instruments, Derivatives and Fair Value Measures Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.2 billion at June 30, 2024 and $7.3 billion at December 31, 2023, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2024 will be included in Cost of products sold at the time the products are sold, generally through the next twelve Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At June 30, 2024 and December 31, 2023, Abbott held the gross notional amounts of $13.0 billion and $13.8 billion, respectively, of such foreign currency forward exchange contracts. Abbott has designated a yen-denominated, 5-year term loan of $573 million and $419 million as of June 30, 2024 and December 31, 2023, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt is due to the net incremental borrowing of $201 million discussed in Note 10 — Debt and Lines of Credit, as well as changes in foreign exchange rates, recorded in Accumulated other comprehensive income (loss), net of tax. Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.2 billion at June 30, 2024 and December 31, 2023 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2024 and December 31, 2023: Fair Value - Assets Fair Value - Liabilities (in millions) June 30, December 31, 2023 Balance Sheet Caption June 30, December 31, 2023 Balance Sheet Caption Interest rate swaps designated as fair value hedges: Non-current $ — $ — Deferred income taxes and other assets $ 74 $ 95 Post-employment obligations, deferred income taxes and other long-term liabilities Current — — Prepaid expenses and other receivables 17 — Other accrued liabilities Foreign currency forward exchange contracts: Hedging instruments 161 88 Prepaid expenses and other receivables 21 134 Other accrued liabilities Others not designated as hedges 49 81 Prepaid expenses and other receivables 36 97 Other accrued liabilities Debt designated as a hedge of net investment in a foreign subsidiary — — n/a 573 419 Long-term debt $ 210 $ 169 $ 721 $ 745 The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2024 and 2023. Gain (loss) Recognized in Other Income (expense) and Gain (loss) Three Months Six Months Three Months Six Months (in millions) 2024 2023 2024 2023 2024 2023 2024 2023 Income Statement Caption Foreign currency forward exchange contracts designated as cash flow hedges $ 111 $ 90 $ 238 $ 27 $ 25 $ 63 $ 43 $ 189 Cost of products sold Debt designated as a hedge of net investment in a foreign subsidiary 23 38 47 33 — — — — n/a Interest rate swaps designated as fair value hedges n/a n/a n/a n/a 28 (6) 4 3 Interest expense Gains of $43 million and $39 million were recognized in the three months ended June 30, 2024 and 2023, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A gain of $135 million and a loss of $64 million were recognized in the six months ended June 30, 2024 and 2023, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line. The carrying values and fair values of certain financial instruments as of June 30, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties. June 30, 2024 December 31, 2023 (in millions) Carrying Fair Carrying Fair Long-term Investment Securities: Equity securities $ 549 $ 549 $ 555 $ 555 Other 328 328 244 244 Total Long-term Debt (14,754) (14,252) (14,679) (14,769) Foreign Currency Forward Exchange Contracts: Receivable position 210 210 169 169 (Payable) position (57) (57) (231) (231) Interest Rate Hedge Contracts: (Payable) position (91) (91) (95) (95) The fair value of the debt was determined based on significant other observable inputs, including current interest rates. The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet: Basis of Fair Value Measurement (in millions) Outstanding Quoted Significant Significant June 30, 2024: Equity securities $ 322 $ 322 $ — $ — Foreign currency forward exchange contracts 210 — 210 — Total Assets $ 532 $ 322 $ 210 $ — Fair value of hedged long-term debt $ 2,056 $ — $ 2,056 $ — Interest rate swap derivative financial instruments 91 — 91 — Foreign currency forward exchange contracts 57 — 57 — Contingent consideration related to business combinations 59 — — 59 Total Liabilities $ 2,263 $ — $ 2,204 $ 59 December 31, 2023: Equity securities $ 326 $ 326 $ — $ — Foreign currency forward exchange contracts 169 — 169 — Total Assets $ 495 $ 326 $ 169 $ — Fair value of hedged long-term debt $ 2,052 $ — $ 2,052 $ — Interest rate swap derivative financial instruments 95 — 95 — Foreign currency forward exchange contracts 231 — 231 — Contingent consideration related to business combinations 112 — — 112 Total Liabilities $ 2,490 $ — $ 2,378 $ 112 The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2023 reflects a payment of $40 million and a $13 million change in the fair value of the remaining contingent consideration. The maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales. Excluding such contingent consideration, the maximum amount that may be due under the other contingent consideration arrangements was estimated at June 30, 2024 to be approximately $115 million, which is dependent upon attaining certain sales thresholds or upon the occurrence of certain events, such as regulatory approvals.

Litigation and Environmental Ma

Litigation and Environmental Matters	6 Months Ended
Litigation and Environmental Matters	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Litigation and Environmental Matters	Note 12 — Litigation and Environmental Matters Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million. Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s milk cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn about the risk of NEC. These lawsuits claim that certain preterm infants suffered injury or death as a result of contracting NEC. Abbott denies the allegations in these lawsuits. In July 2024, a jury in a Missouri state court awarded a plaintiff $495 million in a trial against Abbott. Abbott stands by its products and the information it provided about them, and it plans to appeal this jury’s verdict. Abbott does not believe that it is probable that a material loss will be incurred related to these lawsuits and therefore, no reserves have been recorded for these lawsuits. Given the uncertainty as to the possible outcome in each of these lawsuits, Abbott is unable to reasonably estimate a range of possible loss related to these lawsuits. Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million. The recorded accrual balance at June 30, 2024 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations, except for the cases discussed in the second paragraph of this note, the resolution of which could be material to cash flows or results of operations.

Post-Employment Benefits

Post-Employment Benefits	6 Months Ended
Post-Employment Benefits	Jun. 30, 2024
Postemployment Benefits [Abstract]
Post-Employment Benefits	Note 13 — Post-Employment Benefits Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net costs recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans are as follows: Defined Benefit Plans Medical and Dental Plans Three Months Six Months Three Months Six Months (in millions) 2024 2023 2024 2023 2024 2023 2024 2023 Service cost - benefits earned during the period $ 60 $ 58 $ 121 $ 118 $ 10 $ 10 $ 20 $ 19 Interest cost on projected benefit obligations 116 114 234 228 12 16 27 30 Expected return on plan assets (263) (243) (525) (485) (6) (6) (12) (12) Curtailment gain — (14) — (14) — — — — Net amortization of: Actuarial loss, net 6 3 12 6 (1) (1) (1) (1) Prior service cost (credit) 1 — 1 — (4) (4) (7) (7) Net cost (credit) $ (80) $ (82) $ (157) $ (147) $ 11 $ 15 $ 27 $ 29 Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2024 and 2023, $289 million and $290 million, respectively, were contributed to defined benefit plans. In the first six months of 2024 and 2023, $28 million was contributed, in each year, to the post-employment medical and dental plans.

Taxes on Earnings

Taxes on Earnings	6 Months Ended
Taxes on Earnings	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Taxes on Earnings	Note 14 — Taxes on Earnings Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2024 and 2023, taxes on earnings include approximately $29 million and $9 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of 2024 and 2023, taxes on earnings also include approximately $35 million and $62 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years. Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $90 million to $1.34 billion, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023. In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the 2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott intends to file a petition with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD. In June 2024, Abbott received a Revenue Agent’s Report (RAR) from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary adjustments proposed in the RAR are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott believes that the income reallocation adjustments proposed in the RAR are without merit. The RAR also contains other proposed adjustments and omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 RAR also contested a deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law. Abbott is contesting these RAR findings and intends to continue to do so. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate. The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. A subset of the rules became effective January 1, 2024, and the remaining rules become effective January 1, 2025 or later. Abbott continues to analyze the Pillar 2 model rules. The full implementation of the model rules may have a material impact on Abbott’s condensed consolidated financial statements in the future.

Segment Information

Segment Information	6 Months Ended
Segment Information	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Information	Note 15 — Segment Information Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world. Abbott’s reportable segments are as follows: Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products. Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products. Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment. Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment. Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements. Net Sales to External Customers Operating Earnings Three Months Six Months Three Months Six Months (in millions) 2024 2023 2024 2023 2024 2023 2024 2023 Established Pharmaceutical Products $ 1,294 $ 1,287 $ 2,520 $ 2,476 $ 315 $ 307 $ 582 $ 607 Nutritional Products 2,150 2,076 4,218 4,043 373 308 750 688 Diagnostic Products 2,195 2,317 4,409 5,005 430 437 904 1,088 Medical Devices 4,734 4,295 9,187 8,195 1,507 1,385 2,867 2,463 Total Reportable Segments 10,373 9,975 20,334 19,719 2,625 2,437 5,103 4,846 Other 4 3 7 6 Net sales $ 10,377 $ 9,978 $ 20,341 $ 19,725 Corporate functions and benefit plan costs (80) (71) (146) (148) Net interest expense (58) (61) (119) (113) Share-based compensation (a) (141) (132) (445) (413) Amortization of intangible assets (471) (498) (943) (989) Other, net (b) (268) (39) (407) 15 Earnings before taxes $ 1,607 $ 1,636 $ 3,043 $ 3,198 ______________________________________ (a) Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. (b) Other, net for the three and six months ended June 30, 2024 and 2023 includes charges related to restructurings, the impairment of IPR&D assets and integration costs related to business combinations. Other, net for the three and six months ended June 30, 2024 also includes a loss on the divestiture of a non-core business. Other, net for the six months ended June 30, 2024 also includes impairment charges related to various investments. For the three and six months ended June 30, 2023, Other, net includes income arising from fair value changes in contingent consideration related to previous business combinations.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net earnings	$ 1,302	$ 1,375	$ 2,527	$ 2,693

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
Insider Trading Arrangements	Jun. 30, 2024 shares	Jun. 30, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Robert E. Funck, Jr. [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On May 10, 2024, Robert E. Funck, Jr., the then-Executive Vice President, Finance, adopted a plan for the sale of securities of Abbott that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Funck’s Rule 10b5-1 plan provides for the exercise of up to 45,000 stock options until February 19, 2025.
Name	Robert E. Funck, Jr.
Title	Executive Vice President, Finance
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 10, 2024
Expiration Date	February 19, 2025
Arrangement Duration	285 days
Aggregate Available	45,000	45,000
Hubert L. Allen [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On May 10, 2024, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, adopted a plan for the sale of securities of Abbott that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Allen’s Rule 10b5-1 plan provides for the exercise of up to 157,421 stock options until February 19, 2025.
Name	Hubert L. Allen
Title	Executive Vice President, General Counsel and Secretary
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 10, 2024
Expiration Date	February 19, 2025
Arrangement Duration	285 days
Aggregate Available	157,421	157,421

New Accounting Standards (Polic

New Accounting Standards (Policies)	6 Months Ended
New Accounting Standards (Policies)	Jun. 30, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recent Accounting Standards Not Yet Adopted	Recent Accounting Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
Revenue (Tables)	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Summary of Revenue by Sales Category	The following tables provide detail by sales category: Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 (in millions) U.S. Int’l Total U.S. Int’l Total Established Pharmaceutical Products — Key Emerging Markets $ — $ 988 $ 988 $ — $ 990 $ 990 Other — 306 306 — 297 297 Total — 1,294 1,294 — 1,287 1,287 Nutritionals — Pediatric Nutritionals 564 495 1,059 507 517 1,024 Adult Nutritionals 369 722 1,091 374 678 1,052 Total 933 1,217 2,150 881 1,195 2,076 Diagnostics — Core Laboratory 327 1,002 1,329 311 982 1,293 Molecular 33 94 127 43 98 141 Point of Care 107 49 156 99 43 142 Rapid Diagnostics 345 238 583 508 233 741 Total 812 1,383 2,195 961 1,356 2,317 Medical Devices — Rhythm Management 292 315 607 269 314 583 Electrophysiology 287 340 627 245 308 553 Heart Failure 244 77 321 226 69 295 Vascular 275 449 724 264 451 715 Structural Heart 258 306 564 219 279 498 Neuromodulation 192 51 243 185 42 227 Diabetes Care 637 1,011 1,648 505 919 1,424 Total 2,185 2,549 4,734 1,913 2,382 4,295 Other 4 — 4 3 — 3 Total $ 3,934 $ 6,443 $ 10,377 $ 3,758 $ 6,220 $ 9,978 Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 (in millions) U.S. Int’l Total U.S. Int’l Total Established Pharmaceutical Products — Key Emerging Markets $ — $ 1,916 $ 1,916 $ — $ 1,902 $ 1,902 Other — 604 604 — 574 574 Total — 2,520 2,520 — 2,476 2,476 Nutritionals — Pediatric Nutritionals 1,078 990 2,068 966 982 1,948 Adult Nutritionals 733 1,417 2,150 727 1,368 2,095 Total 1,811 2,407 4,218 1,693 2,350 4,043 Diagnostics — Core Laboratory 637 1,897 2,534 600 1,875 2,475 Molecular 75 181 256 90 198 288 Point of Care 205 90 295 192 84 276 Rapid Diagnostics 826 498 1,324 1,414 552 1,966 Total 1,743 2,666 4,409 2,296 2,709 5,005 Medical Devices — Rhythm Management 563 606 1,169 529 581 1,110 Electrophysiology 556 658 1,214 483 575 1,058 Heart Failure 481 145 626 444 132 576 Vascular 529 884 1,413 482 850 1,332 Structural Heart 491 588 1,079 429 530 959 Neuromodulation 373 96 469 340 83 423 Diabetes Care 1,226 1,991 3,217 984 1,753 2,737 Total 4,219 4,968 9,187 3,691 4,504 8,195 Other 7 — 7 6 — 6 Total $ 7,780 $ 12,561 $ 20,341 $ 7,686 $ 12,039 $ 19,725
Schedule of Changes in Contract Liabilities	Changes in the contract liabilities during the period are as follows: (in millions) Contract Liabilities: Balance at December 31, 2023 $ 545 Unearned revenue from cash received during the period 232 Revenue recognized related to contract liability balance (233) Balance at June 30, 2024 $ 544

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	6 Months Ended
Supplemental Financial Information (Tables)	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
Summary of Allowance for Doubtful Accounts Activity	The following summarizes the activity for the first six months of 2024 related to the allowance for doubtful accounts as of June 30, 2024: (in millions) Allowance for Doubtful Accounts: Balance at December 31, 2023 $ 241 Provisions/charges to income 42 Amounts charged off and other deductions (28) Balance at June 30, 2024 $ 255
Schedule of Long-term Investments	The components of long-term investments as of June 30, 2024 and December 31, 2023 are as follows: (in millions) June 30, December 31, Long-term Investments: Equity securities $ 549 $ 555 Other 328 244 Total $ 877 $ 799

Changes In Accumulated Other _2

Changes In Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes	The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows: Three Months Ended June 30 Cumulative Foreign Net Actuarial (Losses) and Cumulative Gains (Losses) (in millions) 2024 2023 2024 2023 2024 2023 Balance at March 31 $ (6,890) $ (6,594) $ (1,372) $ (1,491) $ 96 $ 46 Other comprehensive income (loss) before reclassifications (152) (52) 3 1 77 80 Amounts reclassified from accumulated other comprehensive income 116 — 4 (7) (17) (54) Net current period comprehensive income (loss) (36) (52) 7 (6) 60 26 Balance at June 30 $ (6,926) $ (6,646) $ (1,365) $ (1,497) $ 156 $ 72 Six Months Ended June 30 Cumulative Foreign Net Actuarial (Losses) and Cumulative Gains (Losses) (in millions) 2024 2023 2024 2023 2024 2023 Balance at January 1 $ (6,504) $ (6,733) $ (1,376) $ (1,493) $ 41 $ 175 Other comprehensive income (loss) before reclassifications (538) 87 5 3 145 38 Amounts reclassified from accumulated other comprehensive income 116 — 6 (7) (30) (141) Net current period comprehensive income (loss) (422) 87 11 (4) 115 (103) Balance at June 30 $ (6,926) $ (6,646) $ (1,365) $ (1,497) $ 156 $ 72

Restructuring Plans (Tables)

Restructuring Plans (Tables)	6 Months Ended
Restructuring Plans (Tables)	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Activity and Related Accruals	The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2024: (in millions) Total Accrued balance at December 31, 2023 $ 137 Payments and other adjustments (69) Accrued balance at June 30, 2024 $ 68

Incentive Stock Programs (Table

Incentive Stock Programs (Tables)	6 Months Ended
Incentive Stock Programs (Tables)	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Options Outstanding and Exercisable	Information regarding the number of options outstanding and exercisable at June 30, 2024 is as follows: Outstanding Exercisable Number of shares 28,058,739 24,125,493 Weighted average remaining life (years) 4.8 4.2 Weighted average exercise price $ 78.94 $ 73.34 Aggregate intrinsic value (in millions) $ 815 $ 815

Financial Instruments, Deriva_2

Financial Instruments, Derivatives and Fair Value Measures (Tables)	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Amounts and Location of Derivative Financial Instruments	The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2024 and December 31, 2023: Fair Value - Assets Fair Value - Liabilities (in millions) June 30, December 31, 2023 Balance Sheet Caption June 30, December 31, 2023 Balance Sheet Caption Interest rate swaps designated as fair value hedges: Non-current $ — $ — Deferred income taxes and other assets $ 74 $ 95 Post-employment obligations, deferred income taxes and other long-term liabilities Current — — Prepaid expenses and other receivables 17 — Other accrued liabilities Foreign currency forward exchange contracts: Hedging instruments 161 88 Prepaid expenses and other receivables 21 134 Other accrued liabilities Others not designated as hedges 49 81 Prepaid expenses and other receivables 36 97 Other accrued liabilities Debt designated as a hedge of net investment in a foreign subsidiary — — n/a 573 419 Long-term debt $ 210 $ 169 $ 721 $ 745
Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)	The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2024 and 2023. Gain (loss) Recognized in Other Income (expense) and Gain (loss) Three Months Six Months Three Months Six Months (in millions) 2024 2023 2024 2023 2024 2023 2024 2023 Income Statement Caption Foreign currency forward exchange contracts designated as cash flow hedges $ 111 $ 90 $ 238 $ 27 $ 25 $ 63 $ 43 $ 189 Cost of products sold Debt designated as a hedge of net investment in a foreign subsidiary 23 38 47 33 — — — — n/a Interest rate swaps designated as fair value hedges n/a n/a n/a n/a 28 (6) 4 3 Interest expense
Schedule of Carrying Values and Fair Values of Financial Instruments	The carrying values and fair values of certain financial instruments as of June 30, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties. June 30, 2024 December 31, 2023 (in millions) Carrying Fair Carrying Fair Long-term Investment Securities: Equity securities $ 549 $ 549 $ 555 $ 555 Other 328 328 244 244 Total Long-term Debt (14,754) (14,252) (14,679) (14,769) Foreign Currency Forward Exchange Contracts: Receivable position 210 210 169 169 (Payable) position (57) (57) (231) (231) Interest Rate Hedge Contracts: (Payable) position (91) (91) (95) (95)
Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis	The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet: Basis of Fair Value Measurement (in millions) Outstanding Quoted Significant Significant June 30, 2024: Equity securities $ 322 $ 322 $ — $ — Foreign currency forward exchange contracts 210 — 210 — Total Assets $ 532 $ 322 $ 210 $ — Fair value of hedged long-term debt $ 2,056 $ — $ 2,056 $ — Interest rate swap derivative financial instruments 91 — 91 — Foreign currency forward exchange contracts 57 — 57 — Contingent consideration related to business combinations 59 — — 59 Total Liabilities $ 2,263 $ — $ 2,204 $ 59 December 31, 2023: Equity securities $ 326 $ 326 $ — $ — Foreign currency forward exchange contracts 169 — 169 — Total Assets $ 495 $ 326 $ 169 $ — Fair value of hedged long-term debt $ 2,052 $ — $ 2,052 $ — Interest rate swap derivative financial instruments 95 — 95 — Foreign currency forward exchange contracts 231 — 231 — Contingent consideration related to business combinations 112 — — 112 Total Liabilities $ 2,490 $ — $ 2,378 $ 112

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	6 Months Ended
Post-Employment Benefits (Tables)	Jun. 30, 2024
Postemployment Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	Net costs recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans are as follows: Defined Benefit Plans Medical and Dental Plans Three Months Six Months Three Months Six Months (in millions) 2024 2023 2024 2023 2024 2023 2024 2023 Service cost - benefits earned during the period $ 60 $ 58 $ 121 $ 118 $ 10 $ 10 $ 20 $ 19 Interest cost on projected benefit obligations 116 114 234 228 12 16 27 30 Expected return on plan assets (263) (243) (525) (485) (6) (6) (12) (12) Curtailment gain — (14) — (14) — — — — Net amortization of: Actuarial loss, net 6 3 12 6 (1) (1) (1) (1) Prior service cost (credit) 1 — 1 — (4) (4) (7) (7) Net cost (credit) $ (80) $ (82) $ (157) $ (147) $ 11 $ 15 $ 27 $ 29

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
Segment Information (Tables)	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements. Net Sales to External Customers Operating Earnings Three Months Six Months Three Months Six Months (in millions) 2024 2023 2024 2023 2024 2023 2024 2023 Established Pharmaceutical Products $ 1,294 $ 1,287 $ 2,520 $ 2,476 $ 315 $ 307 $ 582 $ 607 Nutritional Products 2,150 2,076 4,218 4,043 373 308 750 688 Diagnostic Products 2,195 2,317 4,409 5,005 430 437 904 1,088 Medical Devices 4,734 4,295 9,187 8,195 1,507 1,385 2,867 2,463 Total Reportable Segments 10,373 9,975 20,334 19,719 2,625 2,437 5,103 4,846 Other 4 3 7 6 Net sales $ 10,377 $ 9,978 $ 20,341 $ 19,725 Corporate functions and benefit plan costs (80) (71) (146) (148) Net interest expense (58) (61) (119) (113) Share-based compensation (a) (141) (132) (445) (413) Amortization of intangible assets (471) (498) (943) (989) Other, net (b) (268) (39) (407) 15 Earnings before taxes $ 1,607 $ 1,636 $ 3,043 $ 3,198 ______________________________________ (a) Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. (b) Other, net for the three and six months ended June 30, 2024 and 2023 includes charges related to restructurings, the impairment of IPR&D assets and integration costs related to business combinations. Other, net for the three and six months ended June 30, 2024 also includes a loss on the divestiture of a non-core business. Other, net for the six months ended June 30, 2024 also includes impairment charges related to various investments. For the three and six months ended June 30, 2023, Other, net includes income arising from fair value changes in contingent consideration related to previous business combinations.

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
Revenue - Narrative (Details) $ in Millions	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 USD ($) segment	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 USD ($) segment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Number of reportable segments \| segment	4	4	4	4
Net sales	$ 10,377	$ 9,978	$ 20,341	$ 19,725
Diagnostics
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	4,800		4,800
Diagnostics \| COVID-19 Testing
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Net sales	102	$ 263	306	$ 993
Medical Devices
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 493		$ 493
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Percentage of remaining performance obligation expected to be recognized in period			60%
Expected timing of satisfaction period (in months)	24 months		24 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Percentage of remaining performance obligation expected to be recognized in period			17%
Expected timing of satisfaction period (in months)	12 months		12 months

Revenue - Summary of Revenue by

Revenue - Summary of Revenue by Sales Category (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Net sales	$ 10,377	$ 9,978	$ 20,341	$ 19,725
Operating Segments
Segment Reporting Information [Line Items]
Net sales	10,373	9,975	20,334	19,719
Other
Segment Reporting Information [Line Items]
Net sales	4	3	7	6
United States
Segment Reporting Information [Line Items]
Net sales	3,934	3,758	7,780	7,686
United States \| Other
Segment Reporting Information [Line Items]
Net sales	4	3	7	6
International
Segment Reporting Information [Line Items]
Net sales	6,443	6,220	12,561	12,039
International \| Other
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Established Pharmaceutical Products \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,294	1,287	2,520	2,476
Established Pharmaceutical Products \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Established Pharmaceutical Products \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,294	1,287	2,520	2,476
Nutritionals \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,150	2,076	4,218	4,043
Nutritionals \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	933	881	1,811	1,693
Nutritionals \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,217	1,195	2,407	2,350
Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,195	2,317	4,409	5,005
Diagnostics \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	812	961	1,743	2,296
Diagnostics \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,383	1,356	2,666	2,709
Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	4,734	4,295	9,187	8,195
Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,185	1,913	4,219	3,691
Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,549	2,382	4,968	4,504
Key Emerging Markets \| Established Pharmaceutical Products \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	988	990	1,916	1,902
Key Emerging Markets \| Established Pharmaceutical Products \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Key Emerging Markets \| Established Pharmaceutical Products \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	988	990	1,916	1,902
Other \| Established Pharmaceutical Products \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	306	297	604	574
Other \| Established Pharmaceutical Products \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Other \| Established Pharmaceutical Products \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	306	297	604	574
Pediatric Nutritionals \| Nutritionals \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,059	1,024	2,068	1,948
Pediatric Nutritionals \| Nutritionals \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	564	507	1,078	966
Pediatric Nutritionals \| Nutritionals \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	495	517	990	982
Adult Nutritionals \| Nutritionals \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,091	1,052	2,150	2,095
Adult Nutritionals \| Nutritionals \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	369	374	733	727
Adult Nutritionals \| Nutritionals \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	722	678	1,417	1,368
Core Laboratory \| Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,329	1,293	2,534	2,475
Core Laboratory \| Diagnostics \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	327	311	637	600
Core Laboratory \| Diagnostics \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,002	982	1,897	1,875
Molecular \| Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	127	141	256	288
Molecular \| Diagnostics \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	33	43	75	90
Molecular \| Diagnostics \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	94	98	181	198
Point of Care \| Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	156	142	295	276
Point of Care \| Diagnostics \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	107	99	205	192
Point of Care \| Diagnostics \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	49	43	90	84
Rapid Diagnostics \| Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	583	741	1,324	1,966
Rapid Diagnostics \| Diagnostics \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	345	508	826	1,414
Rapid Diagnostics \| Diagnostics \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	238	233	498	552
Rhythm Management \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	607	583	1,169	1,110
Rhythm Management \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	292	269	563	529
Rhythm Management \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	315	314	606	581
Electrophysiology \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	627	553	1,214	1,058
Electrophysiology \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	287	245	556	483
Electrophysiology \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	340	308	658	575
Heart Failure \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	321	295	626	576
Heart Failure \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	244	226	481	444
Heart Failure \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	77	69	145	132
Vascular \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	724	715	1,413	1,332
Vascular \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	275	264	529	482
Vascular \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	449	451	884	850
Structural Heart \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	564	498	1,079	959
Structural Heart \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	258	219	491	429
Structural Heart \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	306	279	588	530
Neuromodulation \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	243	227	469	423
Neuromodulation \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	192	185	373	340
Neuromodulation \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	51	42	96	83
Diabetes Care \| Medical Devices \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,648	1,424	3,217	2,737
Diabetes Care \| Medical Devices \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	637	505	1,226	984
Diabetes Care \| Medical Devices \| International \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	$ 1,011	$ 919	$ 1,991	$ 1,753

Revenue - Schedule of Changes i

Revenue - Schedule of Changes in Contract Liabilities (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Contract Liabilities:
Beginning balance	$ 545
Unearned revenue from cash received during the period	232
Revenue recognized related to contract liability balance	(233)
Ending balance	$ 544

Supplemental Financial Inform_3

Supplemental Financial Information - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Condensed Cash Flow Statements, Captions [Line Items]
Net earnings allocated to common shares	$ 1,297	$ 1,370	$ 2,517	$ 2,682
Payment of cash taxes			747	837
Securities in mutual funds held in a rabbi trust	311		311
Equity method investments carrying value	162		162
Equity investment without readily determinable fair value	65		65
Established Pharmaceutical Products
Condensed Cash Flow Statements, Captions [Line Items]
Gain (loss) on disposal	143
Net assets	28		28
Foreign currency translation adjustment	$ 116
Defined Benefit Plans
Condensed Cash Flow Statements, Captions [Line Items]
Pension contributions			$ 289	$ 290

Supplemental Financial Inform_4

Supplemental Financial Information - Allowance for Doubtful Accounts (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Allowance for Doubtful Accounts:
Beginning balance	$ 241
Provisions/charges to income	42
Amounts charged off and other deductions	(28)
Ending balance	$ 255

Supplemental Financial Inform_5

Supplemental Financial Information - Investments (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Summary of Investment Holdings [Line Items]
Total	$ 877	$ 799
Equity securities
Summary of Investment Holdings [Line Items]
Total	549	555
Other
Summary of Investment Holdings [Line Items]
Total	$ 328	$ 244

Changes In Accumulated Other _3

Changes In Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period			$ 38,603
Other comprehensive income (loss)	$ 31	$ (32)	(296)	$ (20)
End of the period	39,318		39,318
Cumulative Foreign Currency Translation (Loss) Adjustments
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	(6,890)	(6,594)	(6,504)	(6,733)
Other comprehensive income (loss) before reclassifications	(152)	(52)	(538)	87
Amounts reclassified from accumulated other comprehensive income	116	0	116	0
Other comprehensive income (loss)	(36)	(52)	(422)	87
End of the period	(6,926)	(6,646)	(6,926)	(6,646)
Net Actuarial (Losses) and Prior Service (Costs) and Credits
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	(1,372)	(1,491)	(1,376)	(1,493)
Other comprehensive income (loss) before reclassifications	3	1	5	3
Amounts reclassified from accumulated other comprehensive income	4	(7)	6	(7)
Other comprehensive income (loss)	7	(6)	11	(4)
End of the period	(1,365)	(1,497)	(1,365)	(1,497)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	96	46	41	175
Other comprehensive income (loss) before reclassifications	77	80	145	38
Amounts reclassified from accumulated other comprehensive income	(17)	(54)	(30)	(141)
Other comprehensive income (loss)	60	26	115	(103)
End of the period	$ 156	$ 72	$ 156	$ 72

Business Acquisition (Details)

Business Acquisition (Details) $ / shares in Units, $ in Millions	Apr. 27, 2023 USD ($) intangibleAsset $ / shares	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]
Goodwill		$ 23,308	$ 23,679
CSI
Business Acquisition [Line Items]
Acquisition share price (in dollars per share) \| $ / shares	$ 20
Acquisition purchase price	$ 851
Number of developed technology intangible assets \| intangibleAsset	2
Developed technology intangible asset	$ 305
In-process research and development	15
Goodwill	369
Net deferred tax assets	46
Other net assets	$ 116

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets [Line Items]
Goodwill	$ 23,308	$ 23,308	$ 23,679
Decrease in goodwill due to foreign currency translation adjustments		332
Decrease in goodwill due to purchase accounting finalization for business acquisitions		39
Amount of reductions of goodwill relating to impairments		0
Gross amount of amortizable intangible assets	27,500	27,500	27,700
Accumulated amortization of intangible assets	20,500	20,500	19,700
Decrease in intangible assets due to foreign currency translation adjustments		46
Impairment charge		8
Estimated annual amortization expense, intangible assets, 2024	1,900	1,900
Estimated annual amortization expense, intangible assets, 2025	1,700	1,700
Estimated annual amortization expense, intangible assets, 2026	1,600	1,600
Estimated annual amortization expense, intangible assets, 2027	1,300	1,300
Estimated annual amortization expense, intangible assets, 2028	700	700
Indefinite-lived intangible assets related to in-process R&D acquired in a business combination	798	798	$ 787
Increase in in-process R&D due to acquisition	35
Established Pharmaceutical Products
Goodwill and Intangible Assets [Line Items]
Goodwill	2,600	2,600
Nutritional Products
Goodwill and Intangible Assets [Line Items]
Goodwill	285	285
Diagnostic Products
Goodwill and Intangible Assets [Line Items]
Goodwill	3,500	3,500
Medical Devices
Goodwill and Intangible Assets [Line Items]
Goodwill	16,900	$ 16,900
Impairment of indefinite-lived intangible assets	$ 25

Restructuring Plans - Narrative

Restructuring Plans - Narrative (Details) - 2024 Restructuring Plan $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 59
Payments for restructuring	8
Restructuring reserve	51
Asset impairment charges	28
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	38
Research and Development
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 19

Restructuring Plans - Restructu

Restructuring Plans - Restructuring Activity and Related Accruals (Details) - Streamline Operations Restructuring Plans $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Restructuring Reserve [Roll Forward]
Accrued balance at beginning of the period	$ 137
Payments and other adjustments	(69)
Accrued balance at end of the period	$ 68

Incentive Stock Programs - Narr

Incentive Stock Programs - Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Incentive stock program, shares reserved for future grants (in shares)	60,000,000
Total unrecognized compensation cost \| $	$ 675
Total unrecognized compensation cost, recognition period	3 years
Stock Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted during the period (in shares)	1,683,097
Restricted Stock Awards
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards granted during the period (in shares)	404,597
Restricted Stock Units (RSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock units granted during period (in shares)	5,265,995

Incentive Stock Programs - Opti

Incentive Stock Programs - Options (Details) - Stock Options $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options outstanding, number of shares \| shares	28,058,739
Exercisable options, number of shares \| shares	24,125,493
Stock options outstanding, weighted-average remaining life	4 years 9 months 18 days
Exercisable options, weighted-average remaining life	4 years 2 months 12 days
Stock options outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 78.94
Exercisable options, weighted-average exercise price (in dollars per share) \| $ / shares	$ 73.34
Aggregate intrinsic value of options outstanding \| $	$ 815
Aggregate intrinsic value of options exercisable \| $	$ 815

Debt and Lines of Credit (Detai

Debt and Lines of Credit (Details) $ in Millions, ¥ in Billions	Jun. 26, 2024 USD ($)	Jan. 29, 2024 USD ($)	Nov. 12, 2020	Jun. 30, 2024 USD ($)	Jun. 26, 2024 JPY (¥)	Jun. 25, 2024 JPY (¥)
Revolving Credit Facility \| 2024 Five Year Credit Agreement
Debt Instrument [Line Items]
Debt instrument, term	5 years	5 years
Maximum borrowing capacity				$ 5,000	¥ 92	¥ 59.8
Net proceeds	$ 201
Revolving Credit Facility \| 2024 Five Year Credit Agreement \| Tokyo Interbank Offered Rate
Debt Instrument [Line Items]
Debt instrument, term	5 years
Line of Credit \| 2020 Five Year Credit Agreement
Debt Instrument [Line Items]
Debt instrument, term			5 years
Outstanding borrowings		$ 0

Financial Instruments, Deriva_3

Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) - USD ($) $ in Millions			3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 26, 2024	Jan. 29, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Derivative [Line Items]
Yen-denominated term loan			$ 721		$ 721		$ 745
Payment for contingent consideration					40
Change in fair value of remaining contingent consideration					13
Various Business Acquisitions
Derivative [Line Items]
Maximum amount of contingent consideration			115		$ 115
2024 Five Year Credit Agreement \| Revolving Credit Facility
Derivative [Line Items]
Debt instrument, term	5 years	5 years
Net proceeds	$ 201
Net Investment Hedging \| Designated as Hedging Instrument \| Five Year Term Loan due 2024
Derivative [Line Items]
Debt instrument, term					5 years		5 years
Yen-denominated term loan			573		$ 573		$ 419
Foreign Exchange Forward
Derivative [Line Items]
Gain (loss) from foreign currency forward exchange contracts not designated as hedges			43	$ 39	135	$ (64)
Foreign Exchange Forward \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			13,000		13,000		13,800
Foreign Exchange Forward \| Cash Flow Hedging \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			7,200		$ 7,200		7,300
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold					12 months
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold					18 months
Interest Rate Swap \| Fair Value Hedging \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			$ 2,200		$ 2,200		$ 2,200

Financial Instruments, Deriva_4

Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Fair Value - Assets	$ 210	$ 169
Fair Value - Liabilities	721	745
Designated as Hedging Instrument \| Interest Rate Swap \| Deferred income taxes and other assets \| Fair Value Hedging
Derivatives, Fair Value [Line Items]
Fair Value - Assets	0	0
Designated as Hedging Instrument \| Interest Rate Swap \| Prepaid expenses and other receivables, current \| Fair Value Hedging
Derivatives, Fair Value [Line Items]
Fair Value - Assets	0	0
Designated as Hedging Instrument \| Interest Rate Swap \| Post-employment obligations, deferred income taxes and other long-term liabilities \| Fair Value Hedging
Derivatives, Fair Value [Line Items]
Fair Value - Liabilities	74	95
Designated as Hedging Instrument \| Interest Rate Swap \| Other accrued liabilities \| Fair Value Hedging
Derivatives, Fair Value [Line Items]
Fair Value - Liabilities	17	0
Designated as Hedging Instrument \| Foreign Exchange Forward \| Prepaid expenses and other receivables
Derivatives, Fair Value [Line Items]
Fair Value - Assets	161	88
Designated as Hedging Instrument \| Foreign Exchange Forward \| Other accrued liabilities
Derivatives, Fair Value [Line Items]
Fair Value - Liabilities	21	134
Designated as Hedging Instrument \| Debt \| Long-term debt \| Net Investment Hedging
Derivatives, Fair Value [Line Items]
Fair Value - Liabilities	573	419
Not Designated as Hedging Instrument \| Foreign Exchange Forward \| Prepaid expenses and other receivables
Derivatives, Fair Value [Line Items]
Fair Value - Assets	49	81
Not Designated as Hedging Instrument \| Foreign Exchange Forward \| Other accrued liabilities
Derivatives, Fair Value [Line Items]
Fair Value - Liabilities	$ 36	$ 97

Financial Instruments, Deriva_5

Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Foreign Exchange Forward \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges	$ 111	$ 90	$ 238	$ 27
Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges	25	63	43	189
Debt
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary	23	38	47	33
Interest Rate Swap \| Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges	$ 28	$ (6)	$ 4	$ 3

Financial Instruments, Deriva_6

Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Derivative [Line Items]
Long-term Investment Securities:	$ 877	$ 799
Receivable position	210	169
(Payable) position	(721)	(745)
Equity securities
Derivative [Line Items]
Long-term Investment Securities:	549	555
Carrying Value
Derivative [Line Items]
Total Long-term Debt	(14,754)	(14,679)
Carrying Value \| Foreign Exchange Forward
Derivative [Line Items]
Receivable position	210	169
(Payable) position	(57)	(231)
Carrying Value \| Interest Rate Swap
Derivative [Line Items]
(Payable) position	(91)	(95)
Carrying Value \| Equity securities
Derivative [Line Items]
Long-term Investment Securities:	549	555
Carrying Value \| Other
Derivative [Line Items]
Long-term Investment Securities:	328	244
Fair Value
Derivative [Line Items]
Total Long-term Debt	(14,252)	(14,769)
Fair Value \| Foreign Exchange Forward
Derivative [Line Items]
Receivable position	210	169
(Payable) position	(57)	(231)
Fair Value \| Interest Rate Swap
Derivative [Line Items]
(Payable) position	(91)	(95)
Fair Value \| Equity securities
Derivative [Line Items]
Long-term Investment Securities:	549	555
Fair Value \| Other
Derivative [Line Items]
Long-term Investment Securities:	$ 328	$ 244

Financial Instruments, Deriva_7

Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Quoted Prices in Active Markets
Assets, at Fair Value
Equity securities	$ 322	$ 326
Foreign currency forward exchange contracts	0	0
Total Assets	322	326
Liabilities, at Fair Value
Fair value of hedged long-term debt	0	0
Interest rate swap derivative financial instruments	0	0
Foreign currency forward exchange contracts	0	0
Contingent consideration related to business combinations	0	0
Total Liabilities	0	0
Significant Other Observable Inputs
Assets, at Fair Value
Equity securities	0	0
Foreign currency forward exchange contracts	210	169
Total Assets	210	169
Liabilities, at Fair Value
Fair value of hedged long-term debt	2,056	2,052
Interest rate swap derivative financial instruments	91	95
Foreign currency forward exchange contracts	57	231
Contingent consideration related to business combinations	0	0
Total Liabilities	2,204	2,378
Significant Unobservable Inputs
Assets, at Fair Value
Equity securities	0	0
Foreign currency forward exchange contracts	0	0
Total Assets	0	0
Liabilities, at Fair Value
Fair value of hedged long-term debt	0	0
Interest rate swap derivative financial instruments	0	0
Foreign currency forward exchange contracts	0	0
Contingent consideration related to business combinations	59	112
Total Liabilities	59	112
Outstanding Balances
Assets, at Fair Value
Equity securities	322	326
Foreign currency forward exchange contracts	210	169
Total Assets	532	495
Liabilities, at Fair Value
Fair value of hedged long-term debt	2,056	2,052
Interest rate swap derivative financial instruments	91	95
Foreign currency forward exchange contracts	57	231
Contingent consideration related to business combinations	59	112
Total Liabilities	$ 2,263	$ 2,490

Litigation and Environmental _2

Litigation and Environmental Matters (Details) - USD ($) $ in Millions	1 Months Ended
	Jul. 31, 2024	Jun. 30, 2024
Loss Contingencies [Line Items]
Maximum expected cleanup exposure for individual site		$ 4
Maximum expected cleanup exposure in aggregate		10
Subsequent Event \| NEC
Loss Contingencies [Line Items]
Amount awarded to plaintiff	$ 495
Lawsuit reserves	$ 0
Legal proceedings and environmental exposures
Loss Contingencies [Line Items]
Recorded accrual balance for legal proceedings and exposures		45
Legal proceedings and environmental exposures \| Minimum
Loss Contingencies [Line Items]
Estimation of possible loss		40
Legal proceedings and environmental exposures \| Maximum
Loss Contingencies [Line Items]
Estimation of possible loss		$ 50

Post-Employment Benefits - Sche

Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost - benefits earned during the period	$ 60	$ 58	$ 121	$ 118
Interest cost on projected benefit obligations	116	114	234	228
Expected return on plan assets	(263)	(243)	(525)	(485)
Curtailment gain	0	(14)	0	(14)
Net amortization of:
Actuarial loss, net	6	3	12	6
Prior service cost (credit)	1	0	1	0
Net cost (credit)	(80)	(82)	(157)	(147)
Medical and Dental Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost - benefits earned during the period	10	10	20	19
Interest cost on projected benefit obligations	12	16	27	30
Expected return on plan assets	(6)	(6)	(12)	(12)
Curtailment gain	0	0	0	0
Net amortization of:
Actuarial loss, net	(1)	(1)	(1)	(1)
Prior service cost (credit)	(4)	(4)	(7)	(7)
Net cost (credit)	$ 11	$ 15	$ 27	$ 29

Post-Employment Benefits - Narr

Post-Employment Benefits - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Company contributions	$ 289	$ 290
Medical and Dental Plans
Defined Benefit Plan Disclosure [Line Items]
Company contributions	$ 28	$ 28

Taxes on Earnings (Details)

Taxes on Earnings (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
Taxes on Earnings (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Excess tax benefits associated with share-based compensation		$ 29	$ 9
Tax expense from prior year tax positions		35	$ 62
Decrease reasonably possible in gross unrecognized tax benefits	$ 90	90
Unrecognized tax benefits	1,340	1,340
Statutory notice of deficiency tax claim amount	192	192		$ 417
Revenue agent's report tax claim amount	443	$ 443
Contested cash tax benefit amount	$ 440

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Segment Information (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Net Sales to External Customers	$ 10,377	$ 9,978	$ 20,341	$ 19,725
Operating Earnings	1,669	1,542	3,055	3,051
Amortization of intangible assets	(471)	(498)	(943)	(989)
Earnings before taxes	$ 1,607	$ 1,636	$ 3,043	$ 3,198
Annual share-based awards recognized in first quarter (as a percent)	45%	45%	45%	45%
Operating Segments
Segment Reporting Information [Line Items]
Net Sales to External Customers	$ 10,373	$ 9,975	$ 20,334	$ 19,719
Operating Earnings	2,625	2,437	5,103	4,846
Operating Segments \| Established Pharmaceutical Products
Segment Reporting Information [Line Items]
Net Sales to External Customers	1,294	1,287	2,520	2,476
Operating Earnings	315	307	582	607
Operating Segments \| Nutritional Products
Segment Reporting Information [Line Items]
Net Sales to External Customers	2,150	2,076	4,218	4,043
Operating Earnings	373	308	750	688
Operating Segments \| Diagnostic Products
Segment Reporting Information [Line Items]
Net Sales to External Customers	2,195	2,317	4,409	5,005
Operating Earnings	430	437	904	1,088
Operating Segments \| Medical Devices
Segment Reporting Information [Line Items]
Net Sales to External Customers	4,734	4,295	9,187	8,195
Operating Earnings	1,507	1,385	2,867	2,463
Other
Segment Reporting Information [Line Items]
Net Sales to External Customers	4	3	7	6
Segment Reconciling Items
Segment Reporting Information [Line Items]
Corporate functions and benefit plan costs	(80)	(71)	(146)	(148)
Net interest expense	(58)	(61)	(119)	(113)
Share-based compensation	(141)	(132)	(445)	(413)
Amortization of intangible assets	(471)	(498)	(943)	(989)
Other, net	$ (268)	$ (39)	$ (407)	$ 15